HealthDay News — The current quadrivalent human papillomavirus (HPV) vaccine does not have a significant impact on the recurrence of genital warts in men exposed to HPV infection, according to research published in the Journal of Sexual Medicine.
“Although little is known about HPV infection in men, they are also in the risk group of HPV infection and play an important role in transmitting the virus to women,” explained Enis Rauf Coskuner, MD, of the Acibadem University School of Medicine in Istanbul, and colleagues.
To define the efficacy of the HPV vaccine through cross-immunization and its role in clearance of HPV infection, and to assess the factors associated in men, the investigators enrolled 171 men with genital warts into a randomized clinical study.
Following the initial intervention, patients (mean age, 34 ± 7.6 years) were randomly assigned to three doses of HPV vaccine (n=91) or no vaccination (n=80).
In univariate analysis, the only significant factor in the recurrence of genital warts was marital status; other factors, including age, smoking status, and vaccination status, were not significant. In multivariable analysis, the only significant factor associated with wart recurrence was marital status (hazard ratio, 2.0; P=0.002).
“Married men had more recurrences in our population,” concluded the researchers. “Larger multicenter randomized clinical trials are lacking and seriously required to investigate the therapeutic effect of current quadrivalent HPV vaccine in genital warts.”